Thoracic radiotherapy plus Durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy - employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy: study protocol of the TRADE-hypo trial

BACKGROUND: Non-small cell lung cancer is the most common cause of cancer death worldwide, highlighting the need for novel therapeutic concepts. In particular, there is still a lack of treatment strategies for the group of elderly and frail patients, who are frequently not capable of receiving stand...

Descripción completa

Detalles Bibliográficos
Autores principales: Bozorgmehr, Farastuk, Chung, Inn, Christopoulos, Petros, Krisam, Johannes, Schneider, Marc A., Brückner, Lena, Mueller, Daniel Wilhelm, Thomas, Michael, Rieken, Stefan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447611/
https://www.ncbi.nlm.nih.gov/pubmed/32842974
http://dx.doi.org/10.1186/s12885-020-07264-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7447611/
https://www.ncbi.nlm.nih.gov/pubmed/32842974
http://dx.doi.org/10.1186/s12885-020-07264-8

Ejemplares similares